55-60 kDa (Reducing)
Reconstitute at 0.1-1 mg/ml according to the size in ultrapure water after rapid centrifugation.
1. Dr Maria Corinna A Palanca-Wessels, Prof Myron Czuczman, Prof Gilles Salles, Sarit Assouline, Laurie H Sehn, Ian Flinn, et al; Safety and activity of the anti-CD79B antibody–drug conjugate polatuzumab vedotin in relapsed or refractory B-cell non-Hodgkin lymphoma and chronic lymphocytic leukaemia: a phase 1 study. ARTICLES| VOLUME 16, ISSUE 6, P704-715, JUNE 2015. .
CD79, the signaling component of the B-cell receptor (BCR), is a promising target of antibodies and ADCs for the treatment of B-cell malignancies and autoimmune diseases. CD79 is a heterodimer, consisting of CD79a and CD79b, and is an attractive target because it is B cell specific and is expressed in almost all forms of non-Hodgkin's lymphoma and most forms of chronic lymphocytic leukemia. CD79 is particularly attractive for use as an ADC because the receptor is trafficked to a lysosome-like compartment as part of antigen presentation, thereby providing a mechanism for enhancing the release of drug from the ADC.
1μg (R: reducing condition, N: non-reducing condition).
Immobilized Anti-Human CD79b (Polatuzumab) at 2.0μg/mL (100μL/well) can bind Biotinylated CD79B Fc&Avi Tag, Human (Cat. No. UA010901) with EC50 of 6.10-11.42ng/mL.
您现在的位置：